Ann-Lii Cheng

Ann-Lii Cheng is a leading hepatocellular carcinoma specialist in Asia who contributed to the SHARP and REFLECT trials establishing sorafenib and lenvatinib respectively as systemic therapy standards in advanced HCC. His pioneering work has shaped systemic therapy paradigms for HCC across multiple lines. He leads HCC clinical research at National Taiwan University and contributes to Asia-Pacific oncology guidelines for liver cancer management. Cheng's contributions span biomarker development for HCC systemic therapy to understanding viral hepatitis-related HCC biology.